Molecular Therapy-Oncolytics

Papers
(The H4-Index of Molecular Therapy-Oncolytics is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Ferroptosis gene signature in cholangiocarcinoma83
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence56
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 155
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis48
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation44
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML40
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers37
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma37
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity36
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy36
PROTACs in gastrointestinal cancers35
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer35
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer34
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T31
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy30
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme30
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia29
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges28
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia27
A library of cancer testis specific T cell receptors for T cell receptor gene therapy27
Adding recombinant AAVs to the cancer therapeutics mix26
Radiovirotherapy at twenty26
Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products25
Oncolytic adenovirus for treatment of malignant ascites24
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice24
Bacterial cancer therapy using the attenuated fowl-adapted Salmonella enterica serovar Gallinarum24
ScRNA-seq and bulk RNA-seq reveal the characteristics of ferroptosis and establish a risk signature in cholangiocarcinoma24
0.56783604621887